MAST Blend-200 (DE DP Blend) Oil Steroids Injectable 200mg/ml

Description

MAST Blend Dual-Ester Drostanolone Injectable Research

Molecular Data

• Active Ingredients: Drostanolone Propionate, Drostanolone Enanthate
• CAS Number: 521-12-0 (Propionate), 472-61-1 (Enanthate)
• Molecular Weight: 360.53 g/mol (P) / 416.64 g/mol (E)
• Purity: >99% composite purity confirmed via HPLC-UV and GC/MS
• Appearance: Clear, pale golden viscous lipid solution
• Solubility: Optimized in organic carrier lipids including Miglyol 840 and Ethyl Oleate

Mode of Action

The pharmacology of MAST Blend-200 is rooted in its high affinity for the nuclear androgen receptor (AR) and its structural resistance to aromatase conversion. Drostanolone molecules bind to the androgen receptor to initiate the translocation of the receptor complex into the nucleus, triggering myogenic gene transcription. The 2-methyl modification inhibits the 3α-hydroxysteroid dehydrogenase enzyme, preventing the compound from being deactivated into inactive metabolites within skeletal muscle tissue. The multi-ester matrix regulates systemic bioavailability through a staggered hydrolysis process, where esterases cleave the side chains at different rates. Binding kinetics suggest that MAST Blend-200 also exhibits mild anti-estrogenic properties by potentially competing for the aromatase enzyme or modulating estrogen receptor (ER) sensitivity. Quantitatively, terminal half-life values for the blend exhibit a bimodal distribution peaking at 2.5 days and 9 days (±15%). Unlike single-ester propionate protocols which yield volatile plasma spikes, this 200mg/ml blend maintains a tighter standard deviation in serum concentrations.

Overview

MAST Blend-200 is a sophisticated parenteral AAS formulation engineered to provide a synergistic pharmacokinetic profile by combining short-acting and long-acting esters of drostanolone. This dual-ester system utilizes the immediate receptor saturation of the propionate variant alongside the protracted liberation kinetics of the enanthate ester. Researchers prioritize MAST Blend-200 for investigating the cross-talk between androgenic signaling and lipid metabolism in complex biological models. By bypassing the initial metabolic barriers of oral administration, this oil-based matrix ensures high bioavailability and stable plasma concentrations over extended research durations.

Known Effects

• Accelerated Tissue Hardening: Investigators observe a profound increase in muscle density and visual ‘dryness’ due to the absence of fluid retention.
• Lipolytic Pathway Stimulation: Based on community feedback, effects include a noticeable reduction in subcutaneous adiposity through AR-mediated down-regulation of lipid storage.
• Enhanced Neurological Drive: Experimental findings suggest a significant boost in central nervous system output, facilitating superior force production and aggression.
• Anti-Estrogenic Modulation: Observed effects include a reduction in systemic water retention, making it a focal point for aesthetic refinement studies.
• Positive Nitrogen Flux: Research models show a sustained positive nitrogen balance, which protects lean mass during phases of metabolic stress or caloric restriction.

Key Points:
MAST Blend-200 represents a high-precision research tool for studying pure androgenic signaling and tissue refinement with a uniquely balanced pharmacokinetic profile.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.